Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
QuantumPharm, Inc. ( (HK:2228) ) has issued an announcement.
XtalPi Holdings Limited reported a sharp increase in revenue to RMB802.6 million for the year ended 31 December 2025, up from RMB266.4 million a year earlier, reflecting strong business expansion. The company remained R&D-intensive, with research and development expenses rising to RMB569.2 million, underscoring its continued focus on innovation.
The group swung from a substantial loss of RMB1.51 billion in 2024 to a profit of RMB134.6 million in 2025, with adjusted net profit reaching RMB258.2 million after excluding non-cash and one-off items. The return to profitability and strong top-line growth signal improved operational leverage and financial health, potentially strengthening XtalPi’s positioning and confidence among investors and other stakeholders.
The most recent analyst rating on (HK:2228) stock is a Hold with a HK$12.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
More about QuantumPharm, Inc.
XtalPi Holdings Limited is a technology-driven company focused on applying advanced research and development capabilities, likely in computational or pharmaceutical innovation, to commercial projects. Listed on the Hong Kong Stock Exchange, the group operates through multiple subsidiaries and invests heavily in R&D to support its growth and product pipeline in its chosen markets.
Average Trading Volume: 71,943,052
Technical Sentiment Signal: Hold
Current Market Cap: HK$39.1B
See more data about 2228 stock on TipRanks’ Stock Analysis page.